WO2000042988A1 - Method of identifying and treating inflamed tissue - Google Patents
Method of identifying and treating inflamed tissue Download PDFInfo
- Publication number
- WO2000042988A1 WO2000042988A1 PCT/US2000/001277 US0001277W WO0042988A1 WO 2000042988 A1 WO2000042988 A1 WO 2000042988A1 US 0001277 W US0001277 W US 0001277W WO 0042988 A1 WO0042988 A1 WO 0042988A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leukocytes
- tissue
- adhered
- microbubbles
- shells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 115
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 238000002604 ultrasonography Methods 0.000 claims abstract description 13
- 210000001519 tissue Anatomy 0.000 claims description 58
- 108010088751 Albumins Proteins 0.000 claims description 46
- 102000009027 Albumins Human genes 0.000 claims description 46
- 206010061218 Inflammation Diseases 0.000 claims description 32
- 230000004054 inflammatory process Effects 0.000 claims description 32
- 230000002688 persistence Effects 0.000 claims description 16
- 150000003904 phospholipids Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000012876 carrier material Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 210000003989 endothelium vascular Anatomy 0.000 claims description 5
- 239000002961 echo contrast media Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000002872 contrast media Substances 0.000 abstract description 5
- 208000028867 ischemia Diseases 0.000 description 26
- 238000005096 rolling process Methods 0.000 description 23
- 230000003993 interaction Effects 0.000 description 19
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 210000000264 venule Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 208000027866 inflammatory disease Diseases 0.000 description 14
- 230000004089 microcirculation Effects 0.000 description 13
- 108010044426 integrins Proteins 0.000 description 12
- 102000006495 integrins Human genes 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 230000003511 endothelial effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000004907 flux Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000010410 reperfusion Effects 0.000 description 8
- 238000012285 ultrasound imaging Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000012771 intravital microscopy Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 5
- 206010063837 Reperfusion injury Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004789 organ system Anatomy 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 210000001736 capillary Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 229920002306 Glycocalyx Polymers 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000004517 glycocalyx Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001092081 Carpenteria Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010008908 FS 069 Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000013153 catheter ablation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002607 contrast-enhanced ultrasound Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- CQGGFCOCFOTAHO-UHFFFAOYSA-N n-[4-(2-nitroimidazol-1-yl)butyl]acridin-9-amine;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=NC=CN1CCCCNC1=C(C=CC=C2)C2=NC2=CC=CC=C12 CQGGFCOCFOTAHO-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000038009 orphan disease Diseases 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
Definitions
- the present invention relates to the field of identifying and treating inflamed tissue. DESCRIPTION OF THE BACKGROUND ART
- Physicians and physiologists have long recognized the significance of local perfusion in the assessment and treatment of wounds, inflammatory disorders, viability of transplanted organs and reattached limbs, the diagnosis and treatment of cancerous lesions and the assessment and treatment of disorders of organs.
- Current methods for the diagnosis and treatment of these disorders are expensive, complicated and invasive procedures. It remains clear that fundamental changes in tissue perfusion are involved in disease progression and, in some cases, the onset of the diseased state.
- Cancer currently accounts for 15.8% of the deaths within the United States. Methods for diagnosis are often invasive as in tissue biopsies and are often only as accurate as the technician is experienced with the specific type of cancer. Treatment ranges from radiation and chemotherapy to a variety of experimental therapies. Many of these therapies have common elements in that they are not site-specific and can have an effect on tissues not targeted.
- Cardiovascular diseases are the number one cause of death in developed countries and they cause approximately 38% and 42% of deaths in Canada and the U.S. respectively.
- cardiovascular disease According to a 1993 American Heart Association (AHA) estimate, over 60 million Americans have one or more forms of cardiovascular disease. Each year, cardiovascular disease is responsible for approximately one million fatalities and almost 5 million individuals afflicted with the disease are hospitalized. In 1989, the AHA estimated the cost of treating cardiovascular diseases to be $88.2 billion annually.
- Inflammatory diseases represent a significant concern within the human and animal health fields and considerable investments of money and research time has been spent to fight the numerous disorders falling under this classification. Inflammatory diseases can be autoimmune related, infectious or non-infectious. They can effect almost every organ and tissue type within the body. They can be common, e.g., arthritis affects up to 60% of the adult population, or rare as in lupus which is considered an orphan disease.
- pelvic inflammatory disease is a condition that is common among sufferers of sexually transmitted diseases such as chlamydia or gonorrhea. Millions of new cases are identified each year and experts predict that millions more are undiagnosed and untreated. Diagnostic procedures may be invasive and painful; many women are reluctant to undergo such testing.
- IBD inflammatory bowel disease
- Ulcerative colitis causes ulceration and inflammation of the inner lining of the colon and rectum
- Crohn's disease is an inflammation that extends into the deeper layers of the intestinal wall. Ulcerative colitis and Crohn's disease cause similar symptoms that often resemble other conditions such as irritable bowel syndrome (spastic colitis). The correct diagnosis may take some time and frequently requires invasive techniques such as colonoscopy.
- a method of identifying and/or treating tissue having leukocytes adhered thereto comprises providing a material that selectively attaches to leukocytes adhered to a patient's tissue, and contacting said adhered leukocytes with said material, so as to attach said material to said leukocytes.
- the present invention provides a method for identifying and/or treating inflamed tissue in a patient.
- Inflamed tissue typically has activated leukocytes adhered to vascular endothelium within the inflamed tissue.
- Suitable sites of inflammation in a patient's body include wounds, cancer, and the sites of various inflammatory diseases identified above.
- microbubble shells utilized as ultrasound contrast agents when injected into a patient, attach to activated leukocytes adhered to vascular endothelium in inflamed tissue.
- Suitable microbubble shells can be formed of protein such as albumin and the like, phospholipid, etc.
- the microbubble shells can be filled with any suitable gas, such as air, perfluorocarbon gases and the like.
- inflamed tissue having leukocytes adhered thereto can be identified by introducing ultrasound microbubble shell contrast agent material into a patient's body having tissue not known to have leukocytes adhered thereto. Because the gas- filled microbubble shells attach to activated leukocytes present in inflamed tissue, the site of inflammation can be identified using any suitable ultrasound imaging device. The thus- identified tissue then can be treated utilizing a suitable therapeutic agent.
- tissue having activated leukocytes adhered thereto is identified by the degree of persistence of the gas-filled shells in the inflamed tissue as measured by ultrasound echography utilizing any suitable ultrasound imaging equipment. Accordingly, the amount of inflammation can be quantified based on the degree of persistence of the gas-filled ultrasound microbubble shell contrast agent in the inflamed tissue.
- the gas-filled microbubble shell is utilized as a carrier material for carrying the therapeutic agent to the inflamed tissue.
- the therapeutic agent may be carried in the shell or in the gas.
- the activated leukocytes adhered to the tissue are contacted with the microbubble carrier material and the agent, so as to attach the microbubble material to the leukocytes and thereby treat the tissue with the therapeutic agent.
- the therapeutic agent can be a medicament or insertable gene sequence for delivery to the site of inflammation.
- the shells are bombarded with sufficient ultrasound energy to rupture the shells, and thereby facilitate contacting the tissue with the therapeutic agent.
- Microbubbles can be destroyed by ultrasound energy at certain frequencies and acoustic powers normally used for ultrasound imaging. This property has been utilized to enhance the microbubble signal relative to the background tissue signal, the ability to focally destroy microbubbles with an ultrasound beam and adhesion of microbubbles to activated tissue provides method to deliver drugs (which can be packaged inside the bubble or within the shell) to areas of inflammation. This allows very high local concentrations of drugs without high systemic concentrations, thereby improving drug efficacy without added adverse effects.
- phospholipid membranes can be used as a vector for gene delivery, this can be utilized for the application of microbubble-leukocyte interactions combined with ultrasound imaging to site-specifically deliver genes to regions of inflammation.
- microbubble behavior within a perfused muscle was assessed by performing intravital microscopy following intravenous administration of fluorescent-labeled microbubbles.
- Perfluorocarbon microbubbles with either an albumin or phospholipid shell were studied within the cremaster muscle of wild-type mice at baseline, following ischemia-reperfusion injury of the muscle, and following inflammatory activation with TNF activated invasive ultrasound imaging to diagnose and follow inflammatory disorders.
- these interactions provide a unique opportunity to specifically deliver drugs and genes to sites of inflammation since microbubbles can be ruptured by focused application of ultrasound energy at certain frequencies and energies.
- the effect of treatment on inflamed tissue in a patient can be monitored by periodically quantifying the amount of inflammation so as to determine if a reduction in inflammation of the inflamed tissue has occurred, by repeating the steps outlined above for identifying inflamed tissue in the patient.
- the present invention may be utilized to identify tissue inflammation in a patient, target activated leukocytes in inflamed tissue, quantify the degree of inflammation based on persistence of microbubbles, follow progression of an inflammatory disease, follow response to treatment therapy of an inflammatory disease, deliver drugs or therapeutic gene sequences to cites of inflammation, identify areas of a patient's body not known to have inflammation, . and the like.
- Intravascular administration of gas-filled microbubbles which emit ultrasound energy within an acoustic field permits the evaluation of perfusion in various organs.
- the presence of microbubbles within the microcirculation results in opacification of the insonified tissue, such as the heart during myocardial contrast echocardiography.
- the stability of these microbubbles has been improved by using high molecular weight gases, which are less diffusible, and by encapsulation with a shell composed of albumin, phospholipids, carbohydrates, surfactant, or synthetic polymers. Improved stability and a small size permit transpulmonary passage of microbubbles, thereby making intravenous administration possible.
- Most microbubble agents behave similar to red blood cells and transit unimpeded through the normal microcirculation.
- albumin microbubbles persist in the microcirculation of the heart and produce prolonged opacification during myocardial contrast echocardiography. Without being bound to any particular theory, the persistence of albumin microbubbles may be due to a charge specific interaction between these anionic microbubbles and the vascular endothelium in regions where there is loss of the negatively-charged glycocalyx which coats the luminal surface of the endothelium.
- microbubbles containing perfluorocarbons with either an albumin or phospholipid shell were provided prelabeled with fluorescein by Mallinckrodt Inc. (St. Louis, MO) and injected into the mice intravenously at baseline, following ischemia-reperfusion injury of the muscle, and 2 hours following a potent inflammatory stimulus (TNF).
- TNF potent inflammatory stimulus
- This invention is thus useful for the diagnosis and treatment of inflammatory diseases and disorders, e.g., diagnosis and treatment of cancer, diagnosis and treatment of wounds and disorders of organs including cardiovascular disease; the use thereof to identify specific and potential sites of inflammation relating to these diseases; and the use thereof to deliver therapeutic molecules and/or genes to said sites.
- inflammatory diseases and disorders e.g., diagnosis and treatment of cancer, diagnosis and treatment of wounds and disorders of organs including cardiovascular disease; the use thereof to identify specific and potential sites of inflammation relating to these diseases; and the use thereof to deliver therapeutic molecules and/or genes to said sites.
- the invention can be used in either humans or animals.
- DMSO dimethyl sulfoxide
- fMLP N-formyl-methionine-leucine-phenylalanine
- HPF high power field
- mAb monoclonal antibody
- PBS phosphate buffered saline
- PMA phorbol 12-myristate 13-acetate
- RBC red blood cells
- TNF tumor necrosis factor Background - Albumin microbubbles used during myocardial contrast echocardiography persist in the microcirculation of injured tissue. This study was performed to determine the mechanism and molecular determinants for microbubble persistence. 7
- TNF resulted in a much greater (p ⁇ 0.001) adherence of albumin (39 ⁇ 7 hpf), PL " (36 ⁇ 10 hpf), and PL + (29 ⁇ 8 hpf) microbubbles.
- microbubbles were observed to attach to leukocytes adhered to the endothelium in post-capillary venules.
- Flow cytometry revealed that albumin microbubble adherence to activated leukocytes could be blocked by mAb against leukocyte integrins ⁇ m ⁇ 2 (MAC-1) and ⁇ 4 ⁇ , (VLA-4) in combination.
- Perfluorocarbon-filled microbubbles (Mallinckrodt Inc., St. Louis, MO) with shells comprised of either negatively-charged denatured albumin (Optison ® ) or phospolipids with a net negative (MP1950 " ) or positive (MP1950 + ) charge were used in this study. Fluorescent labeling of the microbubbles was achieved by an amide . The mean size for the albumin, MP1950 " , and
- MP1950 + microbubbles was 3.9, 5.4, and 4.3 ⁇ m, respectively.
- the concentration of each agent was measured prior to every experiment using a hemocytometer (Fisher Scientific, Pittsburgh, PA) and ranged between 1.8 and 4.0 ⁇ l0 8 /mL " '.
- Murine anti-human mAb were used for the in vitro experiments to block interactions known to occur between denatured albumin and leukocyte integrins Mac-1 ( ⁇ m ⁇ 2 ) and NLA-4
- mice were anesthetized with an intraperitoneal injection (12.5 ⁇ L/g "1 ) of a solution containing ketamine hydrocholoride (10 mg/mL "1 ), xylazine (1 mg/mL "1 ) and atropine (0.02 mg/mL "1 ). Body temperature was maintained at 37°C with a heating pad. Both jugular veins were cannulated with polyethylene tubing for administration of microbubbles and drugs. Anesthesia was maintained with intravenous administration of 0.1 mg pentobarbital approximately every 45 min as needed.
- the cremaster muscle was prepared for intravital microscopy as previously described. Either the right or left cremaster muscle was exteriorized through a scrotal incision and secured to a translucent pedestal. A longitudinal incision was made in the muscle, the edges were secured to the pedestal, and the epididymis and testicle were gently pinned to the side. The cremaster muscle was superfused continuously with isothermic bicarbonate-buffered saline. Intravital microscopy
- Epifluorescence was performed using an excitation filter for fluorescein (450-490 nm) with a light source interfaced with a strobe (model 11360, Chadwick-Helmuth, El Monte, CA) flashing at 30 Hz.
- Video recordings were made using a high resolution camera (VE-1000CD, Dage-MTI, Michigan City, IN) connected to a S-VHS recorder (Panasonic, Matsushita Electric Co., Secaucus, NJ).
- Centerline venular RBC velocities were measured using a dual photodiode and converted to mean blood flow velocities by multiplying by an empirical factor of 0.625.
- Shear rates ( ⁇ w ) were determined by the equation:
- Venular diameters were measured off-line using video calipers. Freeze-frame advancing allowed tracking of individual rolling leukocytes over a distance of 30 to 100 ⁇ m. The total distance traveled was divided by the elapsed time to derive the mean rolling velocity. The number of rolling leukocytes was determined by counting leukocytes crossing a line perpendicular to the vessel for 1 min. Leukocyte rolling flux fraction (F), which reflects the percent of leukocytes passing through a venule that are rolling, was calculated by:
- F r n (0.25%d 2 IV b l601C L ) A where r fret is number of rolling leukocytes in 1 minute, d is vessel diameter, V b is centerline blood velocity, and C L is the systemic leukocyte blood concentration.
- Adherent leukocytes defined as those not moving for at least 30 sec, were counted and expressed per surface area of the venule, calculated from diameter and length assuming cylindrical geometry of the venule.
- Cremaster muscles from 8 wild-type mice were used to assess the microbubble behavior following ischemia and reperfusion injury.
- Blood flow was then interrupted for 30 to 90 min using a ligature placed around the cremasteric artery and, if present, around the major feeding artery connecting the cremaster to the epididymis.
- the microcirculation was monitored to ensure cessation of flow over the entire ischemic period.
- microbubble administration was again performed in random order.
- the three venular segments recorded prior to ischemia were then identified by anatomic landmarks for post-reperfusion video recordings and velocity measurements.
- mice Four wild-type mice were studied to assess microbubble behavior in a model of inflammation induced by TNF-cc activation. Intrascrotal injections of 0.5 ⁇ g murine recombinant TNF- ⁇ (Genzyme Corp., Cambridge, MA) in 0.2 mL sterile saline were performed 2 hours prior to dissection of the cremaster muscle. Video recordings and velocity measurements of 3 venules and microbubble injections were performed in a manner similar to the ischemia-reperfusion protocol. Flow cytometry
- Blood was obtained from healthy adult volunteers, anticoagulated with heparin (10 U/mL " '), and centrifuged to separate the cellular and serum components. The cellular fraction was washed and leukocytes were fluorescently labeled by the addition of rhodamine-6-G (Molecular
- Red blood cells were hypotonically lysed and samples were analyzed using a laser flow cytometer (FACScan, Beckton-Dickson, San Jose, CA). Differences between leukocyte and microbubble side and forward light scatter permitted exclusion (by live gating) of free microbubbles from analysis. Data are presented as green (fluorescein) versus red (rhodamine) fluorescence and as histograms of green fluorescence in a gated population.
- mice undergoing cremasteric ischemia died during arterial occlusion, precluding reflow data in these animals.
- the duration of ischemia in the remaining mice was 30, 60 and 90 min (2 mice each).
- Venular hemodynamic data were taken from all mice.
- mean blood velocity and shear rate were slightly higher following reflow compared to baseline, probably as a result of hyperemia, but these differences did not reach statistical significance.
- Leukocyte rolling in post-capillary venules was observed prior to ischemia.
- TNF- ⁇ resulted in a very high number of adhered leukocytes which, together with leukocyte transmigration, were probably responsible for the low calculated leukocyte flux fraction.
- microbubble adherence was uncommon at baseline. Following ischemia and reperfusion, adherence of albumin and MP1950 " microbubbles was observed in venules only. Following TNF- ⁇ , there was much greater venular attachment for all 3 microbubble preparations. In almost all instances, microbubbles appeared to attach to the surface of leukocytes adhered to the endothelial surface of venules. Venules from 2 different mice were observed following ischemia-reperfusion (panel A) and following TNF- ⁇ activation (panel B).
- Activated leukocytes (A) labeled with Rhodamine-6G exhibited high activity in the red spectrum but with little overlap into the green spectrum.
- the appearance of events in the upper right quadrant (combined red and green fluorescence) when cells were combined with the different preparations of fluorescein-labeled microbubbles in the presence of serum indicated interactions between the two. Recorded events were gated according to forward and side scatter to exclude the smaller free microbubbles and variability in the extent of green fluorescence probably represented variation in both the number of microbubbles attached and microbubble size.
- microbubble behavior in the microcirculation of the mouse cremaster muscle. Under normal conditions, microbubbles were observed to pass through the microcirculation unimpeded. Following either ischemia-reperfusion or TNF- ⁇ activation, albumin and phospholipid microbubbles persisted in post-capillary venules by means of their binding to activated leukocytes on the endothelial surface. Direct interactions between microbubbles and injured microvascular endothelium was rarely observed.
- leukocyte rolling in itself, does not denote leukocyte activation but, instead, represents an initial step of the inflammatory cascade whereby capture of leukocytes facilitates both time-dependent activation by local chemokines and subsequent development of higher affinity bonds with low forward reaction rates.
- the higher affinity bonds that result in arrest of leukocytes (and transmigration) are mediated by leukocyte integrins which, when activated, interact with immunoglobulin receptors (IC AM- 1 , VC AM- 1 ) on the endothelial surface.
- IC AM- 1 , VC AM- 1 immunoglobulin receptors
- Leukocyte adhesion within venules was more pronounced following ischemia- reperfusion and TNF- ⁇ activation, especially with the latter. It was this population of cells that interacted with microbubbles. As a result, the extent of microbubble persistence in the microcirculation correlated with adhesion density but not rolling flux fraction.
- albumin microbubbles preferentially adhere to activated leukocytes is also supported by non-specific interactions known to occur between leukocyte integrins and a wide variety of proteins.
- ⁇ 2 integrins which play a critical role in neutrophil and monocyte adhesion and extravascular transmigration, bind to a diverse range of protein substrates other than endothelial immunoglobulin adhesion molecules, including fibrinogen, fibronectin, vitronectin, laminin, casein, and albumin.
- Isolated human leukocytes and monocyte-differentiated HL-60 cells have been shown to bind to albumin following their activation with PMA or fMLP.
- Mac- 1 -mediated adhesion is much greater with denatured rather than native albumin, promoting the concept that neutrophils may be directed to regions of abnormal extracellular matrix and retained in injured tissue by means of ⁇ 2 integrin binding to denatured proteins.
- denatured albumin has been shown to be a chemotactic factor for neutrophils.
- microbubbles attach to specific leukocyte adhesion molecules that are activated and play a major role in leukocyte adhesion during inflammation or bind in a non- specific or indirect (complement-mediated) fashion, the extent of binding appears to reflect the extent of leukocyte adherence very early in the inflammatory cascade.
Abstract
A method of identifying and/or treating tissue having leukocytes adhered thereto which utilizes a material that selectively attaches to leukocytes adhered to a patient's tissue. The material may be a gas-filled microbubble contrast agent which selectively attaches to activated leukocytes present in inflamed tissue. The microbubbles attached to activated leukocytes may be located by ultrasound echography, and inflamed tissue may be treated by a drug or gene sequence carried by the microbubble contrast agent.
Description
METHOD OF IDENTIFYING AND TREATING INFLAMED TISSUE
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to the field of identifying and treating inflamed tissue. DESCRIPTION OF THE BACKGROUND ART
Physicians and physiologists have long recognized the significance of local perfusion in the assessment and treatment of wounds, inflammatory disorders, viability of transplanted organs and reattached limbs, the diagnosis and treatment of cancerous lesions and the assessment and treatment of disorders of organs. Current methods for the diagnosis and treatment of these disorders are expensive, complicated and invasive procedures. It remains clear that fundamental changes in tissue perfusion are involved in disease progression and, in some cases, the onset of the diseased state.
Cancer currently accounts for 15.8% of the deaths within the United States. Methods for diagnosis are often invasive as in tissue biopsies and are often only as accurate as the technician is experienced with the specific type of cancer. Treatment ranges from radiation and chemotherapy to a variety of experimental therapies. Many of these therapies have common elements in that they are not site-specific and can have an effect on tissues not targeted.
Cardiovascular diseases are the number one cause of death in developed countries and they cause approximately 38% and 42% of deaths in Canada and the U.S. respectively.
According to a 1993 American Heart Association (AHA) estimate, over 60 million Americans have one or more forms of cardiovascular disease. Each year, cardiovascular disease is responsible for approximately one million fatalities and almost 5 million individuals afflicted with the disease are hospitalized. In 1989, the AHA estimated the cost of treating cardiovascular diseases to be $88.2 billion annually.
Inflammatory diseases represent a significant concern within the human and animal health fields and considerable investments of money and research time has been spent to fight the numerous disorders falling under this classification. Inflammatory diseases can be autoimmune related, infectious or non-infectious. They can effect almost every organ and tissue type within the body. They can be common, e.g., arthritis affects up to 60% of the adult
population, or rare as in lupus which is considered an orphan disease. Diseases such as arthritis, inflammatory bowel syndrome, inflammatory liver syndrome, keratitis, lupus, ocular inflammatory disease, restinosis, psoriasis and other inflammations related to auto-immune disorders, gout, Paget's disease and lime disease represent examples of the variety of inflammatory disorders that afflict humans and animals.
As an example, pelvic inflammatory disease is a condition that is common among sufferers of sexually transmitted diseases such as chlamydia or gonorrhea. Millions of new cases are identified each year and experts predict that millions more are undiagnosed and untreated. Diagnostic procedures may be invasive and painful; many women are reluctant to undergo such testing.
A second example, inflammatory bowel disease (IBD) is a group of chronic disorders that cause inflammation or ulceration in the small and large intestines. Most often IBD is classified as ulcerative colitis or Crohn's disease but may be referred to as colitis, enteritis, ileitis, and proctitis. Ulcerative colitis causes ulceration and inflammation of the inner lining of the colon and rectum, while Crohn's disease is an inflammation that extends into the deeper layers of the intestinal wall. Ulcerative colitis and Crohn's disease cause similar symptoms that often resemble other conditions such as irritable bowel syndrome (spastic colitis). The correct diagnosis may take some time and frequently requires invasive techniques such as colonoscopy. Physicians and researchers of the pharmaceutical industry are looking for new and effective ways of targeting drugs and genes to sites of inflammation, to areas of tissue damage and to cancerous lesions. Many delivery schemes have been developed, primarily through the formulation and coating of the drug with chemical components that modify release profiles, increase the half-life and improve general pharmacokinetic profiles. Pharmacologists have also developed numerous vehicles for delivering therapeutics into the patients, including injectable solutions, nasal sprays, oral medications, and transdermal systems, among others. Most recently, several biochemical schemes have been developed to target the drug or gene to the disease site. These schemes include linkage of antibodies or antibody fragments with the therapeutic compound, use of liposomes as delivery vehicles, and coating with specific sugars that only degrade under bacterial action. Although significant investments of capital and manpower have been made to create new delivery systems, the majority of therapeutic compounds continue to be delivered using standard techniques.
There remains a need in the art for improved methods of identifying and treating inflamed tissue. SUMMARY OF THE INVENTION
In accordance with the present invention, a method of identifying and/or treating tissue having leukocytes adhered thereto comprises providing a material that selectively attaches to leukocytes adhered to a patient's tissue, and contacting said adhered leukocytes with said material, so as to attach said material to said leukocytes. DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method for identifying and/or treating inflamed tissue in a patient. Inflamed tissue typically has activated leukocytes adhered to vascular endothelium within the inflamed tissue. Suitable sites of inflammation in a patient's body include wounds, cancer, and the sites of various inflammatory diseases identified above.
It has been discovered that materials such as gas-filled microbubble shells utilized as ultrasound contrast agents when injected into a patient, attach to activated leukocytes adhered to vascular endothelium in inflamed tissue. Suitable microbubble shells can be formed of protein such as albumin and the like, phospholipid, etc. The microbubble shells can be filled with any suitable gas, such as air, perfluorocarbon gases and the like.
In accordance with one embodiment, inflamed tissue having leukocytes adhered thereto can be identified by introducing ultrasound microbubble shell contrast agent material into a patient's body having tissue not known to have leukocytes adhered thereto. Because the gas- filled microbubble shells attach to activated leukocytes present in inflamed tissue, the site of inflammation can be identified using any suitable ultrasound imaging device. The thus- identified tissue then can be treated utilizing a suitable therapeutic agent.
Because the ultrasound microbubble shells attached to activated leukocytes, tissue having activated leukocytes adhered thereto is identified by the degree of persistence of the gas-filled shells in the inflamed tissue as measured by ultrasound echography utilizing any suitable ultrasound imaging equipment. Accordingly, the amount of inflammation can be quantified based on the degree of persistence of the gas-filled ultrasound microbubble shell contrast agent in the inflamed tissue. In accordance with one embodiment, the gas-filled microbubble shell is utilized as a carrier material for carrying the therapeutic agent to the inflamed tissue. In accordance with this embodiment, the therapeutic agent may be carried in the shell or in the gas. The activated
leukocytes adhered to the tissue are contacted with the microbubble carrier material and the agent, so as to attach the microbubble material to the leukocytes and thereby treat the tissue with the therapeutic agent. The therapeutic agent can be a medicament or insertable gene sequence for delivery to the site of inflammation. In accordance with one embodiment, after the gas-filled shells are injected into the patient and attached to the leukocytes, the shells are bombarded with sufficient ultrasound energy to rupture the shells, and thereby facilitate contacting the tissue with the therapeutic agent.
Microbubbles can be destroyed by ultrasound energy at certain frequencies and acoustic powers normally used for ultrasound imaging. This property has been utilized to enhance the microbubble signal relative to the background tissue signal, the ability to focally destroy microbubbles with an ultrasound beam and adhesion of microbubbles to activated tissue provides method to deliver drugs (which can be packaged inside the bubble or within the shell) to areas of inflammation. This allows very high local concentrations of drugs without high systemic concentrations, thereby improving drug efficacy without added adverse effects.
Moreover, since phospholipid membranes can be used as a vector for gene delivery, this can be utilized for the application of microbubble-leukocyte interactions combined with ultrasound imaging to site-specifically deliver genes to regions of inflammation.
In order to determine the mechanism of microbubble persistence in the microcirculation in the setting of endothelial injury, we directly assessed microbubble behavior within a perfused muscle by performing intravital microscopy following intravenous administration of fluorescent-labeled microbubbles. Perfluorocarbon microbubbles with either an albumin or phospholipid shell were studied within the cremaster muscle of wild-type mice at baseline, following ischemia-reperfusion injury of the muscle, and following inflammatory activation with TNF activated invasive ultrasound imaging to diagnose and follow inflammatory disorders. Moreover, these interactions provide a unique opportunity to specifically deliver drugs and genes to sites of inflammation since microbubbles can be ruptured by focused application of ultrasound energy at certain frequencies and energies.
In preferred embodiments, the effect of treatment on inflamed tissue in a patient can be monitored by periodically quantifying the amount of inflammation so as to determine if a reduction in inflammation of the inflamed tissue has occurred, by repeating the steps outlined above for identifying inflamed tissue in the patient.
The present invention may be utilized to identify tissue inflammation in a patient, target activated leukocytes in inflamed tissue, quantify the degree of inflammation based on persistence of microbubbles, follow progression of an inflammatory disease, follow response to treatment therapy of an inflammatory disease, deliver drugs or therapeutic gene sequences to cites of inflammation, identify areas of a patient's body not known to have inflammation, . and the like.
Intravascular administration of gas-filled microbubbles which emit ultrasound energy within an acoustic field permits the evaluation of perfusion in various organs. During ultrasound imaging, the presence of microbubbles within the microcirculation results in opacification of the insonified tissue, such as the heart during myocardial contrast echocardiography. The stability of these microbubbles has been improved by using high molecular weight gases, which are less diffusible, and by encapsulation with a shell composed of albumin, phospholipids, carbohydrates, surfactant, or synthetic polymers. Improved stability and a small size permit transpulmonary passage of microbubbles, thereby making intravenous administration possible. Most microbubble agents behave similar to red blood cells and transit unimpeded through the normal microcirculation.
In the setting of endothelial injury produced by ischemia-reperfusion or cardioplegia delivery, albumin microbubbles persist in the microcirculation of the heart and produce prolonged opacification during myocardial contrast echocardiography. Without being bound to any particular theory, the persistence of albumin microbubbles may be due to a charge specific interaction between these anionic microbubbles and the vascular endothelium in regions where there is loss of the negatively-charged glycocalyx which coats the luminal surface of the endothelium.
To determine the mechanism of microbubble persistence, we performed intravital microscopy on the cremaster muscle of wild-type mice in order to directly visualize the microbubble behavior within the microcirculation in a variety of settings. Microbubbles containing perfluorocarbons with either an albumin or phospholipid shell were provided prelabeled with fluorescein by Mallinckrodt Inc. (St. Louis, MO) and injected into the mice intravenously at baseline, following ischemia-reperfusion injury of the muscle, and 2 hours following a potent inflammatory stimulus (TNF). The number of persistent microbubbles was related to the number of leukocytes that were adhered to the vessel wall.
These results imply tremendous clinical potential for albumin or phospholipid microbubbles to be used for imaging inflammatory disorders. Inflammation of any type requires the recruitment of circulating leukocytes into the surrounding tissue. The initial step of this process is the binding of activated leukocytes to the venular endothelium so that they may escape from the intravascular space. There is great interest in the mechanisms of leukocyte attachment to the endothelium, since interrupting this step may provide a means to treat inflammatory disorders. Our discovery of microbubble attachment of activated leukocytes provides a very unique opportunity to image inflammatory states in almost any organ system using ultrasound. This technique may be utilized not only for diagnostic purposes but also for following disease progression or response to therapy. This technique is advantageous due to the ease and safety of the technique, the widespread availability of ultrasound imaging systems, ability to perform bedside or portable studies, and the capability of obtaining immediate results.
This invention is thus useful for the diagnosis and treatment of inflammatory diseases and disorders, e.g., diagnosis and treatment of cancer, diagnosis and treatment of wounds and disorders of organs including cardiovascular disease; the use thereof to identify specific and potential sites of inflammation relating to these diseases; and the use thereof to deliver therapeutic molecules and/or genes to said sites. The invention can be used in either humans or animals. EXAMPLE
ABBREVIATIONS AND ACRONYMS DMSO = dimethyl sulfoxide fMLP = N-formyl-methionine-leucine-phenylalanine HPF = high power field mAb = monoclonal antibody
PBS = phosphate buffered saline PMA = phorbol 12-myristate 13-acetate RBC = red blood cells TNF = tumor necrosis factor Background - Albumin microbubbles used during myocardial contrast echocardiography persist in the microcirculation of injured tissue. This study was performed to determine the mechanism and molecular determinants for microbubble persistence.
7
Methods and Results - Intravital microscopy of the microcirculation of exteriorized cremaster muscle was performed in 14 mice during intravenous injections of fluorescein-labeled microbubbles composed of albumin, PL", and PL+. In 8 mice, injections were performed at baseline and following 30-90 minutes of ischemia with reperfusion. In 4 mice, injections were made 2 hours following TNF preactivation. Compared to baseline where few microbubbles (<2 hpf ') adhered in the microcirculation, ischemia-reperfusion resulted in greater (p<0.05) adherence of albumin (9±5 hpf) and PL" (5±4 hpf) microbubbles. TNF resulted in a much greater (p<0.001) adherence of albumin (39±7 hpf), PL" (36±10 hpf), and PL+ (29±8 hpf) microbubbles. In all instances, microbubbles were observed to attach to leukocytes adhered to the endothelium in post-capillary venules. Flow cytometry revealed that albumin microbubble adherence to activated leukocytes could be blocked by mAb against leukocyte integrins αmβ2 (MAC-1) and α4β, (VLA-4) in combination. Phospholipid microbubble adherence to activated leukocytes was partially blocked by mAb against MAC-1 and completely blocked in complement inactivated serum. Conclusions - Microvascular persistence of microbubbles in the setting of inflammation is due to their attachment to activated leukocytes adherent to venular endothelium. Microbubble- leukocyte interactions are mediated by integrins and serum complement for albumin and phospholipid microbubbles, respectively. These results have important implications for diagnostic ultrasound imaging of inflammatory conditions and for novel methods of drug delivery. In a normal heart, the microvascular rheology of sonicated albumin microbubbles used to assess myocardial perfusion during myocardial contrast echocardiography is similar to RBC. We have previously shown, however, that the microcirculatory transit of sonicated albumin microbubbles is abnormally prolonged in myocardial regions undergoing ischemia and reperfusion. The exact mechanism for persistence of albumin microbubbles in injured tissue is not known but has been postulated to be due to either charge-specific interactions with the microvasculature where the endothelial glycocalyx is compromised, or direct adherence to inflammatory endothelial extracellular matrix.
In the present study, intravital microscopy was used to elucidate the mechanism of prolonged microbubble transit following ischemia-reperfusion. Based on preliminary observations, it appears that both albumin and phospholipid microbubbles bind directly to activated leukocytes which are adherent to the venular endothelial surface in the setting of microvascular injury or inflammation. It further appears that microbubble-leukocyte interactions
are mediated by serum complement proteins and/or leukocyte integrins since these factors are recognized to mediate leukocyte interactions with liposomes and denatured albumin, which form the shells of several commercially available microbubble agents. This hypothesis was tested by in vitro assessment of the determinants of leukocyte-mi crobubble adhesion. METHODS
Microbubbles and Antibodies
Perfluorocarbon-filled microbubbles (Mallinckrodt Inc., St. Louis, MO) with shells comprised of either negatively-charged denatured albumin (Optison®) or phospolipids with a net negative (MP1950") or positive (MP1950+) charge were used in this study. Fluorescent labeling of the microbubbles was achieved by an amide . The mean size for the albumin, MP1950", and
MP1950+ microbubbles was 3.9, 5.4, and 4.3 μm, respectively. The concentration of each agent was measured prior to every experiment using a hemocytometer (Fisher Scientific, Pittsburgh, PA) and ranged between 1.8 and 4.0χl08/mL"'.
Murine anti-human mAb were used for the in vitro experiments to block interactions known to occur between denatured albumin and leukocyte integrins Mac-1 (αmβ2) and NLA-4
(α4β,). These mAb included 2LPM19c (Dako Corp., Carpenteria, CA), an IgGl mAb against the human CD1 lb component of Mac-1, and P4G9 (Dako Corp.), an IgG3 mAb against the human CD49d component ofVLA-4. A non-specific murine IgGl antibody (Biodesign International, Kennebunk, ME) with no known cross reactivity with human cells was used for control purposes. Flow cytometry using FITC-conjugated goat anti-mouse IgG F(ab ')2 (Biodesign International) for secondary labeling of the murine mAb confirmed binding of 2LPM19c mostly to neutrophils and monocytes and P4G9 mostly to lymphocytes. Only trace binding of the control antibody was detected. Complement-deficient human serum (Quidell Corp., San Diego, CA), depleted of C3 by treatment with methylamine, containing 2 mM CaCl2 and MgCl2 was used to assess the role of complement in microbubble-leukocyte interactions.
Animal Preparation
The study protocol was approved by the animal research committee at the University of Virginia. Twelve wild-type male C57BL/6 mice weighing between 24 and 30 g were used. Mice were anesthetized with an intraperitoneal injection (12.5 μL/g"1) of a solution containing ketamine hydrocholoride (10 mg/mL"1), xylazine (1 mg/mL"1) and atropine (0.02 mg/mL"1). Body temperature was maintained at 37°C with a heating pad. Both jugular veins were cannulated with
polyethylene tubing for administration of microbubbles and drugs. Anesthesia was maintained with intravenous administration of 0.1 mg pentobarbital approximately every 45 min as needed. The cremaster muscle was prepared for intravital microscopy as previously described. Either the right or left cremaster muscle was exteriorized through a scrotal incision and secured to a translucent pedestal. A longitudinal incision was made in the muscle, the edges were secured to the pedestal, and the epididymis and testicle were gently pinned to the side. The cremaster muscle was superfused continuously with isothermic bicarbonate-buffered saline. Intravital microscopy
Microscopic observations were made using an intravital microscope (Axioscop FS, Carl Zeiss, Inc., Thornwood, NY) with a saline immersion objective (S W 40/0.75 numerical aperture).
Epifluorescence was performed using an excitation filter for fluorescein (450-490 nm) with a light source interfaced with a strobe (model 11360, Chadwick-Helmuth, El Monte, CA) flashing at 30 Hz. Video recordings were made using a high resolution camera (VE-1000CD, Dage-MTI, Michigan City, IN) connected to a S-VHS recorder (Panasonic, Matsushita Electric Co., Secaucus, NJ). Centerline venular RBC velocities were measured using a dual photodiode and converted to mean blood flow velocities by multiplying by an empirical factor of 0.625. Shear rates (γw) were determined by the equation:
(γw) = 2.12(8 6 ' where Vb is the mean blood velocity, d is the vessel diameter, and 2.12 is a median empirical correction factor.
Venular diameters were measured off-line using video calipers. Freeze-frame advancing allowed tracking of individual rolling leukocytes over a distance of 30 to 100 μm. The total distance traveled was divided by the elapsed time to derive the mean rolling velocity. The number of rolling leukocytes was determined by counting leukocytes crossing a line perpendicular to the vessel for 1 min. Leukocyte rolling flux fraction (F), which reflects the percent of leukocytes passing through a venule that are rolling, was calculated by:
F= rn(0.25%d2IVbl601CL)A where r„ is number of rolling leukocytes in 1 minute, d is vessel diameter, Vb is centerline blood velocity, and CL is the systemic leukocyte blood concentration. Adherent leukocytes, defined as those not moving for at least 30 sec, were counted and expressed per surface area of the venule, calculated from diameter and length assuming cylindrical geometry of the venule. In vivo Protocols
Cremaster muscles from 8 wild-type mice were used to assess the microbubble behavior following ischemia and reperfusion injury. Prior to ischemia, 3 venules with diameters between 25 and 40 μm were recorded under transillumination for 1 min each followed by measurement of centerline blood velocity. Intravenous injections of each microbubble agent were performed in random order. Approximately 4.0x107 microbubbles (volume range 100 - 220 μL) were injected over 20s. Two minutes following each injection, 50 random hpf encompassing arterioles, venules, and capillaries were scanned over approximately 2 minutes using fluorescent epi-illumination. Brief transillumination was used to confirm the presence of normal flow in a vessel when adherent microbubbles were identified. Blood flow was then interrupted for 30 to 90 min using a ligature placed around the cremasteric artery and, if present, around the major feeding artery connecting the cremaster to the epididymis. The microcirculation was monitored to ensure cessation of flow over the entire ischemic period. Following 20 min of reflow, microbubble administration was again performed in random order. The three venular segments recorded prior to ischemia were then identified by anatomic landmarks for post-reperfusion video recordings and velocity measurements.
Four wild-type mice were studied to assess microbubble behavior in a model of inflammation induced by TNF-cc activation. Intrascrotal injections of 0.5 μg murine recombinant TNF-α (Genzyme Corp., Cambridge, MA) in 0.2 mL sterile saline were performed 2 hours prior to dissection of the cremaster muscle. Video recordings and velocity measurements of 3 venules and microbubble injections were performed in a manner similar to the ischemia-reperfusion protocol. Flow cytometry
Blood was obtained from healthy adult volunteers, anticoagulated with heparin (10 U/mL" '), and centrifuged to separate the cellular and serum components. The cellular fraction was washed and leukocytes were fluorescently labeled by the addition of rhodamine-6-G (Molecular
Probes Inc., Eugene, OR) to a final concentration of 1 μM for 30 min. Cells were then washed twice, resuspended in PBS, and analyzed for leukocyte concentration using hemocytometer measurements of Kimura-stained samples. Leukocytes were activated by 10 nM PMA (Sigma Chemical Co., St. Louis, MO) dissolved in DMSO (Sigma Chemical Co.) for 15 min at 37 °C. Serum fractions from the normal volunteers and complement deficient serum were kept on ice until just prior to use.
11
Approximately 2xl06 leukocytes in 0.2 mL of PBS containing 2 mM MgCl2 were incubated at 37°C for 3 minutes with 2xl07 albumin, MP1950", or MP1950+ microbubbles in the presence of either serum, complement-deficient serum, or PBS containing 2 mM MgCL2 to a total volume of 0.4 mL. To some of these samples, 10 μg of IgG, isotype control antibody and mAbs 2LPM19c and P4G9, alone and in combination, were added prior to the addition of microbubbles.
Red blood cells were hypotonically lysed and samples were analyzed using a laser flow cytometer (FACScan, Beckton-Dickson, San Jose, CA). Differences between leukocyte and microbubble side and forward light scatter permitted exclusion (by live gating) of free microbubbles from analysis. Data are presented as green (fluorescein) versus red (rhodamine) fluorescence and as histograms of green fluorescence in a gated population.
Statistical Analysis
Data are expressed as mean±SD. Comparisons were made by 1-way repeated-measures ANONA Correlations between leukocyte rolling or adherence and microbubble persistence were made by multiple regression analysis. Differences were considered significant at p<0.05 (2- sided).
RESULTS In vivo experiments
Two of the 8 mice undergoing cremasteric ischemia died during arterial occlusion, precluding reflow data in these animals. The duration of ischemia in the remaining mice was 30, 60 and 90 min (2 mice each). Venular hemodynamic data were taken from all mice. In mice undergoing ischemia-reperfusion, mean blood velocity and shear rate were slightly higher following reflow compared to baseline, probably as a result of hyperemia, but these differences did not reach statistical significance. Leukocyte rolling in post-capillary venules was observed prior to ischemia. The mean rolling velocity (36.9 ± 19.3 μm/s 1) and flux fraction (0.19±0.06) was consistent with those previously measured early after exteriorization of the cremaster and is mediated by P-selectin expression following surgical trauma. Following ischemia and reperfusion, the leukocyte rolling velocity and flux fraction decreased, although the change in the latter did not reach statistical significance. The mean number of adherent leukocytes almost doubled following ischemia and reperfusion. There was no relation between the duration of ischemia and either rolling flux fraction or number of adherent leukocytes and all reperfusion data was therefore pooled.
Compared to ischemia-reperfusion injury, TNF-α resulted in markedly slower mean leukocyte rolling velocity, despite only mild differences in shear rate. This observation is consistent with E-selectin and integrin-mediated slow rolling following cytokine-induced inflammation. TNF-α resulted in a very high number of adhered leukocytes which, together with leukocyte transmigration, were probably responsible for the low calculated leukocyte flux fraction.
In animals undergoing cremasteric ischemia, microbubble adherence was uncommon at baseline. Following ischemia and reperfusion, adherence of albumin and MP1950" microbubbles was observed in venules only. Following TNF-α, there was much greater venular attachment for all 3 microbubble preparations. In almost all instances, microbubbles appeared to attach to the surface of leukocytes adhered to the endothelial surface of venules. Venules from 2 different mice were observed following ischemia-reperfusion (panel A) and following TNF-α activation (panel B). Images obtained by transillumation (left panels) demonstrated a greater degree of leukocyte adherence following TNF-α since most of the leukocytes in panel A were rolling and about 60% in panel B were adhered. Fluorescent epi-illumination (right panels) of the same venular segments following injection of albumin microbubbles revealed microbubbles attached to individual adhered leukocytes (A) and clusters of leukocytes (B) adhered to the venular surface. Occasionally, adherent leukocytes coupled with microbubbles were observed to release and either roll for a short distance and adhere in a new location or join streamline flow, conveying the microbubble with them. All microbubbles observed rolling along the endothelial surface appeared to be physically associated with a slowly rolling leukocyte and constituted only 6% of all microbubbles interacting with leukocytes. The degree of leukocyte adherence correlated with the venular persistence of albumin (r=0.72, p=0.004), MP1950" (r=0.73, p=0.01), and MP1950+ (r=0.53, p=O.03) microbubbles. No correlation was found between the leukocyte rolling flux fraction and microbubbles adhered. Potential mechanisms of interactions between leukocytes and microbubbles were evaluated using flow cytometry. Activated leukocytes (A) labeled with Rhodamine-6G exhibited high activity in the red spectrum but with little overlap into the green spectrum. The appearance of events in the upper right quadrant (combined red and green fluorescence) when cells were combined with the different preparations of fluorescein-labeled microbubbles in the presence of serum indicated interactions between the two. Recorded events were gated according to forward and side scatter to exclude the smaller free microbubbles and variability in the extent of green fluorescence probably represented variation in both the number of microbubbles attached and
microbubble size. The fraction of leukocytes with microbubbles attached for albumin, MP1950", and MP1950+ microbubbles 50%, 51%, and 32%, respectively. Inhibition of albumin microbubble attachment to leukocytes by blocking Mac-1 was observed by histograms of green fluorescent activity. PMA-activated leukocytes (A) exhibited little green fluorescent activity whereas albumin microbubbles (B) were strongly fluorescent. When incubated together (C), leukocyte-microbubble complexes were evident by the appearance of fluorescence on neutrophils (free microbubbles were again excluded from this analysis by their scatter characteristics). Interactions between albumin microbubbles and neutrophils were largely blocked by the mAb against the CD1 lb component of Mac-1 (D). Inhibition of Mac-1 resulted in 63% reduction in albumin microbubble binding to activated leukocytes. No apparent inhibition occurred with either the control antibody or the mAb for the CD49d component of VLA-4 or when incubations were performed in PBS or complement- depleted serum. Corresponding results for MP1950" and MP1950+ were obtained.
DISCUSSION Until now, the mechanisms responsible for albumin microbubble persistence within the microcirculation following injury have been speculative. In the present study, we discovered that albumin and phospholipid microbubbles, irrespective of charge, bind to activated leukocytes that have adhered to post-capillary venules following ischemia and reperfusion injury and during inflammation induced by TNF-α. Our flow cytometery results suggest that interactions between leukocytes and albumin microbubbles are mediated, in part, by leukocyte integrins that play a major role in inflammation. Together, these findings indicate that microbubble agents traditionally used to assess perfusion in organ systems also may be utilized for the assessment of a wide variety of inflammatory disorders. Mechanisms of Microbubble-Leukocyte Interactions
In order to define the mechanisms responsible for persistent myocardial opacification following albumin microbubble injections into injured vascular beds, we directly observed microbubble behavior in the microcirculation of the mouse cremaster muscle. Under normal conditions, microbubbles were observed to pass through the microcirculation unimpeded. Following either ischemia-reperfusion or TNF-α activation, albumin and phospholipid microbubbles persisted in post-capillary venules by means of their binding to activated leukocytes on the endothelial surface. Direct interactions between microbubbles and injured microvascular endothelium was rarely observed. The methods used to produce inflammation in this study result in a significant heterogeneity in the extent of leukocyte adhesion between vessels and, by
14 observing 50 HPF, we were able to confirm that microbubble adherence preferentially occurred in venular segments with the greatest leukocyte accumulation and did not occur in regions devoid of leukocytes.
Our hypothesis that microbubbles adhere to activated leukocytes by means of leukocyte adhesion molecules was based, in part, on observations made during intravital microscopy. In this and other studies, trauma incurred during exteriorization of the cremaster muscle resulted in leukocyte rolling in venules. This leukocyte rolling results from high dissociation rate bonds between endothelial P-selectin, which is rapidly translocated to the surface from Weibel-Palade bodies, and its glycoprotein ligand PSGL-1 on the leukocyte surface. Despite a mean rolling flux fraction of 0.19 prior to ischemia, attachment of microbubbles to rolling leukocytes at baseline was rare. The phenomenon of leukocyte rolling, in itself, does not denote leukocyte activation but, instead, represents an initial step of the inflammatory cascade whereby capture of leukocytes facilitates both time-dependent activation by local chemokines and subsequent development of higher affinity bonds with low forward reaction rates. The higher affinity bonds that result in arrest of leukocytes (and transmigration) are mediated by leukocyte integrins which, when activated, interact with immunoglobulin receptors (IC AM- 1 , VC AM- 1 ) on the endothelial surface. Firm leukocyte adherence at baseline caused by surgical trauma in this study was present only to a small degree and is normally not observed until greater than 1 hour after exteriorization of the muscle. Leukocyte adhesion within venules was more pronounced following ischemia- reperfusion and TNF-α activation, especially with the latter. It was this population of cells that interacted with microbubbles. As a result, the extent of microbubble persistence in the microcirculation correlated with adhesion density but not rolling flux fraction.
The concept that albumin microbubbles preferentially adhere to activated leukocytes is also supported by non-specific interactions known to occur between leukocyte integrins and a wide variety of proteins. β2 integrins, which play a critical role in neutrophil and monocyte adhesion and extravascular transmigration, bind to a diverse range of protein substrates other than endothelial immunoglobulin adhesion molecules, including fibrinogen, fibronectin, vitronectin, laminin, casein, and albumin. Isolated human leukocytes and monocyte-differentiated HL-60 cells have been shown to bind to albumin following their activation with PMA or fMLP. These interactions are almost entirely inhibited by monoclonal antibody blockade of the CD 18 subunit of the β2 integrins and, more specifically, by antibodies specific for Mac-1 (CD1 lb/CD18). Mac- 1 -mediated adhesion is much greater with denatured rather than native albumin, promoting the
concept that neutrophils may be directed to regions of abnormal extracellular matrix and retained in injured tissue by means of β2 integrin binding to denatured proteins. Similarly, denatured albumin has been shown to be a chemotactic factor for neutrophils. In the current study, in vitro interactions between activated leukocytes and albumin microbubbles, the shells of which contain mostly albumin that has been denatured by thermal energy during sonication, were inhibited by
63% by an antibody against Mac-1. Accordingly, ischemia-reperfusion and TNF-α, both of which result in an inflammatory response characterized by β2 integrin-dependent leukocyte adhesion, resulted in microbubble binding to leukocytes. Clinical relevance of microbubble-leukocyte interactions Persistent myocardial opacification has been observed during myocardial contrast echocardiography with albumin microbubbles in the setting of microvascular injury produced by ischemia-reperfusion, crystalloid cardioplegic arrest, and radio frequency catheter ablation. In these studies, the microbubble appearance (wash-in) rates, derived from time-intensity data, were essentially normal whereas the decay (washout) rates were prolonged. These findings are consistent with our observations that microbubbles attach to leukocytes which adhere to post- capillary venules and not to arterioles or capillaries. The initial studies of cardiac ischemia demonstrated a relation between ischemic duration (up to 45 min) and adherence of albumin microbubbles during reperfusion. This finding is consistent with influence of ischemic time on leukocyte adherence in different tissues/organ systems which appear to be dependent upon the extent of Mac-1 activation. The absence of a relation between ischemic time and either leukocyte adherence or microbubble persistence in the current study may be attributable to relatively longer durations of ischemia.
Regardless of whether microbubbles attach to specific leukocyte adhesion molecules that are activated and play a major role in leukocyte adhesion during inflammation or bind in a non- specific or indirect (complement-mediated) fashion, the extent of binding appears to reflect the extent of leukocyte adherence very early in the inflammatory cascade.
The ability to quantify the degree of microvascular inflammation in a variety of organ systems and disease states using a non-invasive technique such as contrast-enhanced ultrasound may provide a very attractive alternative to many current techniques that are invasive (biopsy) or indirect (serologic markers). The safety and efficacy of many different microbubble contrast agents has already been established.
Claims
CLAIMS L A method of treating tissue having leukocytes adhered thereto, comprising - providing a material that selectively attaches to leukocytes adhered to a patient's tissue, said material being a carrier material carrying an agent for treating said tissue; and - contacting said adhered leukocytes with said carrier material and said agent, so as to attach said carrier material to said leukocytes and treat said tissue with said agent.
2. The method of claim 1 wherein said leukocytes adhered to said tissue are activated leukocytes.
3. The method of claim 1, wherein said carrier material is comprised of gas-filled microbubble shells.
4. The method of claim 3 wherein said agent is carried in said shell or in said gas.
5. The method of claim 3 wherein said shell is comprised of protein or phospholipid.
6. The method of claim 3 wherein said shell is comprised of albumin.
7. The method of claim 1 wherein said tissue is inflamed tissue.
8. The method of claim 7 wherein said leukocytes are adhered to vascular endothelium in said inflamed tissue.
9. The method of claim 3 wherein said gas-filled shells comprise an ultrasound contrast agent when injected into the patient.
10. The method of claim 9 wherein, after said gas-filled shells are attached to said leukocytes, said shells are bombarded with sufficient ultrasound energy to rupture said shells, so as to contact said tissue with said agent.
17 11. A method of identifying and treating tissue having leukocytes adhered thereto, comprising: A) providing a material that selectively attaches to leukocytes adhered to tissue in a patient's body; B) introducing said material into an area of the patient's body having tissue not known to have leukocytes adhered thereto; C) identifying tissue in the patient's body having leukocytes adhered thereto by locating where said material is attached to the adhered leukocytes; D) treating said tissue with a therapeutic agent.
12. The method of claim 10 wherein said tissue is inflamed tissue.
13. The method of claim 10 wherein said leukocytes are activated leukocytes.
14. The method of claim 11 wherein said leukocytes are adhered to vascular endothelium in said inflamed tissue.
15. The method of claim 10 wherein said material is comprised of gas-filled microbubble shells.
16. The method of claim 14 wherein said shells are comprised of protein or phospholipid.
17. The method of claim 14 wherein said shells are comprised of albumin.
18. The method of claim 14 wherein said gas-filled shells comprise an ultrasound contrast agent when injected into said patients body.
19. The method of claim 14 wherein said tissue having leukocytes adhered thereto is identified by a degree of persistence of the gas-filled shells in the inflamed tissue as measured by ultrasound echography.
18 20. The method of claim 18, further comprising the step of quantifying an amount of inflammation of said tissue based on the degree of persistence of said gas-filled shells in said inflamed tissue.
21. The method of claim 19, further comprising repeating steps (A) through (C), and further quantifying said amount of inflammation, so as to determine if a reduction in inflammation of said inflamed tissue has occurred.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11679399P | 1999-01-21 | 1999-01-21 | |
US60/116,793 | 1999-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042988A1 true WO2000042988A1 (en) | 2000-07-27 |
Family
ID=22369261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001277 WO2000042988A1 (en) | 1999-01-21 | 2000-01-20 | Method of identifying and treating inflamed tissue |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2000042988A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7211248B2 (en) | 2001-07-10 | 2007-05-01 | Sonogene, L.L.C. | Enhancement of transfection of DNA into the liver |
US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
CN101780284B (en) * | 2009-01-15 | 2012-05-30 | 南方医科大学南方医院 | Magnetic molecular targeted ultrasound contrast agent microsphere and preparation method thereof |
US20140276775A1 (en) * | 2013-03-14 | 2014-09-18 | Empire Technology Development Llc | Identification of surgical smoke |
US9101745B2 (en) | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
US9255907B2 (en) | 2013-03-14 | 2016-02-09 | Empire Technology Development Llc | Identification of surgical smoke |
RU2613321C2 (en) * | 2011-09-19 | 2017-03-15 | Дженерал Электрик Компани | Complexes based on micro-bubbles and methods of application |
EP3381929A1 (en) | 2017-03-31 | 2018-10-03 | Rigshospitalet | Targeted microbubbles for detection of glycocalyx |
-
2000
- 2000-01-20 WO PCT/US2000/001277 patent/WO2000042988A1/en active Application Filing
Non-Patent Citations (4)
Title |
---|
BROWN J.M. ET AL.: "Contrast Enhanced Sonography of Visceral Perfusion Defects in Dogs", JOURNAL OF ULTRASOUND MEDICINE, vol. 16, 1997, pages 493 - 499, XP002927318 * |
DALECKI D. ET AL.: "The Influence of Contrast Agents on Hemorrhage Produced by Lithotripter Fields", ULTRASOUND IN MEDICINE AND BIOLOGY, vol. 23, no. 9, 1997, pages 1435 - 1439, XP002927319 * |
ROVAI D. ET AL.: "Residual Myocardial Perfusion in Reversibly Damaged Myocardium by Dipyridamole Contrast Echocardiography", EUROPENA HEART JOURNAL, vol. 17, 1996, pages 296 - 301, XP002927316 * |
VILLANUEVA F.S. ET AL.: "Albumin Microbubble Adherence to Human Coronary Endothelium: Implications for Assessment of Endothelial Function Using Myocardial Contrast Echocardiography", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 30, no. 3, September 1997 (1997-09-01), pages 689 - 693, XP002927317 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7211248B2 (en) | 2001-07-10 | 2007-05-01 | Sonogene, L.L.C. | Enhancement of transfection of DNA into the liver |
US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
CN101780284B (en) * | 2009-01-15 | 2012-05-30 | 南方医科大学南方医院 | Magnetic molecular targeted ultrasound contrast agent microsphere and preparation method thereof |
RU2613321C2 (en) * | 2011-09-19 | 2017-03-15 | Дженерал Электрик Компани | Complexes based on micro-bubbles and methods of application |
US10004760B2 (en) | 2011-09-19 | 2018-06-26 | General Electric Company | Microbubble complexes and methods of use |
US20140276775A1 (en) * | 2013-03-14 | 2014-09-18 | Empire Technology Development Llc | Identification of surgical smoke |
WO2014142927A1 (en) * | 2013-03-14 | 2014-09-18 | Empire Technology Development Llc | Identification of surgical smoke |
US9101745B2 (en) | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
US9255907B2 (en) | 2013-03-14 | 2016-02-09 | Empire Technology Development Llc | Identification of surgical smoke |
US9393328B2 (en) | 2013-03-14 | 2016-07-19 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
EP3381929A1 (en) | 2017-03-31 | 2018-10-03 | Rigshospitalet | Targeted microbubbles for detection of glycocalyx |
WO2018178386A1 (en) | 2017-03-31 | 2018-10-04 | Rigshospitalet | Targeted microbubbles for detection of glycocalyx |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lindner et al. | Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin-and complement-mediated adherence to activated leukocytes | |
Piccio et al. | Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric Gi-linked receptors | |
Lanza et al. | A novel site-targeted ultrasonic contrast agent with broad biomedical application | |
US7387994B2 (en) | Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent | |
US10357448B2 (en) | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi | |
US20100196284A1 (en) | Ultrasound Imaging with Targeted Microbubbles | |
EP3042668A1 (en) | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy | |
WO2007038249A9 (en) | Ultrasonic concentration of carrier particles | |
AU2002334266A1 (en) | Vascular occlusion solid-phase agent with immobilised platelet binding agent | |
Riess | Fluorocarbon-based injectable gaseous microbubbles for diagnosis and therapy | |
James et al. | Critical role of the α4 integrin/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL/faslpr mice | |
Tsutsui et al. | Detection of retained microbubbles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction | |
WO2000042988A1 (en) | Method of identifying and treating inflamed tissue | |
CA2337361C (en) | Targeted site specific drug delivery compositions and method of use | |
US20020044959A1 (en) | Targeting drug/gene carriers to irradiated tissue | |
Lindner | Assessment of inflammation with contrast ultrasound | |
JP2002515887A (en) | Use of hollow microcapsules in diagnosis and therapy | |
Rowin et al. | Intracellular calcium requirements for β1 integrin activation | |
CN110292583B (en) | Application of fullerol and composition thereof in preparation of antithrombotic drugs | |
US20050186264A1 (en) | Targeting drug/gene carriers to irradiated tissue | |
Zachary et al. | Vascular lesions and s-thrombomodulin concentrations from auricular arteries of rabbits infused with microbubble contrast agent and exposed to pulsed ultrasound | |
US20160074482A1 (en) | Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent | |
Clark et al. | Neutrophil adhesion in central nervous system ischemia in rabbits | |
Kee et al. | Use of acoustically active contrast agents in imaging of inflammation and atherosclerosis | |
Lindner | Targeted ultrasound contrast agents: Diagnostic and therapeutic potential |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |